Opinion Cubist: more good news for superbug drug.

The article reports that the Food and Drug Administration (FDA) of the United States has granted Cubist Pharmaceutical Inc.'s Cubicin priority review status in acute bacteremia and endocarditis. Cubicin, Cubist's only approved product so far, was initially launched in the U.S. market in November 2003. The drug, a cyclic lipopetide belonging to a new class of antibacterials is approved for the treatment of skin and skin-structure infections. Cubist Pharmaceuticals' Cubicin has been granted priority review status by the FDA for an additional indication in patients with bacteremia with known or suspected endocarditis caused by Staphylococcus aureus.